Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/08—Antiseborrheics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents

Definitions

• Seborrheic dermatitis also known as seborrheic eczema and seborrhea, is a chronic superficial inflammatory disease of the skin capable of affecting many parts of the body including the scalp, eyebrows, nasolabial creases, lips, ears, sternal area, axillae, submammary folds, umbilicus, groins, and gluteul crease.
• the disease is characterized by many shapes, sizes, and surface textures and is often crust-like, yellowish, and accompanied by itching. This is also characterized by remission and exacerbation.
• psoriasis typically differentiates over seborrheic dermatitis in its absence of itching and its resistance treatment by compounds, such as, selenium sulfide and zinc pvrithonate which have been employed in the treatment of seborrheic conditions.
• polymycin B- hydrocortisone i.e., a cortisone-medicated antibiotic
• the instant invention derives from the school which views soborrheic dermatitis as essentially fungal and, as such, caused by organisms at the largest end of the spectrum of microscopic organisms. That is, organisms larger than bacteria, but is still not visible to human eye. These include as yet undetected microorganisms, amenable or responsive to treatment with topical ivermectin.
• the present invention constitutes a method of treatment of seborrheic dermatitis consisting of the application, in the form of either a lotion or a cream, of a mixture comprising a therapeutically effective amount of ivermectin in water in a concentration of about 750 micrograms per milliliter (mcg/ml), in the case of a lotion, and with a pharmaceutically acceptable carrier if used as a cream.
• a lotion or cream is applied nightly for a period of seven days and then employed on a maintenance basis one to four times per month.
• ivermectin which is a part of a larger chemical family known as the 13-deoxy aglycones
• 13-deoxy aglycones has historically been a product of Merck & Co., Inc., Rahway, New Jersey. It, historically, been employed in veterinary applications for the treatment of endoparasitic conditions in animals.
• some medical papers, particularly from the third world and tropical regions have suggested that the topical use of ivermectin in humans in the treatment of internal or endoparasatic conditions, such as myiasis and onchocerciasis.
• these conditions have no known pathogenic or histologic connection to seborrheic dermatitis or, for that matter, to any known form of psoriasis.
• no publication known to the within inventor has ever suggested employment of topical ivermectin in the treatment of any form of dermatitis.
• the instant invention entails the use of a therapeutically effective quantity of ivermectin, generally available from Merck as a paste, which, when dissolved in water, is sufficient to form a lotion having a concentration of at least 750 meg per ml.
• a cream of ivermectin may be formed, this in combination with a pharmaceutically acceptable carrier such as propylene glycol, sodium lauryl sulfate, zanthan gum, or combinations thereof.
• the lotion or cream is then applied on a daily basis for seven days and, thereafter, one to four times per month on the affected area to prevent recurrence of the condition.
• ivermectin With respect to mechanism of action, it is believed that the effect of ivermectin upon the skin relates principally to sebaceous glands which exist in almost every follicule of the human skin, and are vulnerable to attack by fungii. Accordingly, therein the fungus theory as well as the hormonal dysfunction theory of seborrheic dermatitis is addressed. Also, due to the relaxation effect on the skin which has been demonstrated in the application thereto of ivermectin, the theory of etiology relative to emotional stress and associated increased perspiration as a cause of seborrheic dermatitis, is also addressed. As such, the quieting and desensitizing effect of ivermectin is believed to subdue the motor lability to thereby reduce capillary stress associated with the condition.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Dermatology (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=24425042

Family Applications (1)

Country Status (10)

Families Citing this family (18)

Family Cites Families (8)

• 2000
  • 2000-06-29 US US09/605,747 patent/US6319945B1/en not_active Expired - Lifetime
• 2001
  • 2001-06-27 EP EP01984091A patent/EP1294375B1/en not_active Expired - Lifetime
  • 2001-06-27 CN CNB018018572A patent/CN1171588C/zh not_active Expired - Fee Related
  • 2001-06-27 DE DE60116302T patent/DE60116302T2/de not_active Expired - Lifetime
  • 2001-06-27 AU AU2002216748A patent/AU2002216748A1/en not_active Abandoned
  • 2001-06-27 CA CA002384448A patent/CA2384448C/en not_active Expired - Fee Related
  • 2001-06-27 WO PCT/US2001/041159 patent/WO2002002056A2/en not_active Ceased
  • 2001-06-27 JP JP2002506679A patent/JP3802485B2/ja not_active Expired - Fee Related
  • 2001-06-27 AT AT01984091T patent/ATE314068T1/de not_active IP Right Cessation
  • 2001-06-27 ES ES01984091T patent/ES2252312T3/es not_active Expired - Lifetime
  • 2001-10-12 US US09/976,914 patent/US6433006B2/en not_active Expired - Lifetime

Also Published As

Similar Documents

Legal Events